KMCAR Phase 1 First-in-Human: Novel Target, Zero Efficacy Data, Crowded Approved Field

HaemaLogiX Doses First Patient in KOALA Trial for Multiple Myeloma

HaemaLogiX has initiated its Phase I KOALA clinical trial, dosing the first patient with KMCAR T-cell therapy for relapsed or refractory kappa-restricted multiple myeloma. Conducted at the Peter MacCallum Cancer Centre in Australia, this marks the first human administration of the KMCAR T-cell immunotherapy. The treatment was well tolerated, with no serious adverse events reported, and a second patient is now enrolled for a higher dose. KMCAR T-cell therapy targets the Kappa Myeloma Antigen (KMA) to selectively eliminate malignant plasma cells, aiming to preserve normal immune function.

• The first patient treated with KMCAR T-cell therapy in the Phase I KOALA trial demonstrated good tolerability with no serious adverse events. Following this positive initial outcome, a second patient has been enrolled and is slated to receive treatment at a higher dose, indicating progression in the dose-escalation study.
• KMCAR T-cell therapy is designed to specifically target the Kappa Myeloma Antigen (KMA), which is exclusively found on malignant plasma cells. This precise targeting aims to differentiate it from current therapies by eliminating cancerous cells while preserving healthy immune cells, thereby potentially reducing the risk of immunodeficiency and life-threatening infections.
• The primary objective of the KOALA trial is to evaluate the safety and initial efficacy signals of KMCAR T-cell therapy. The study focuses on patients with relapsed or refractory multiple myeloma who have exhausted standard treatments and are not suitable for other CAR-T cell therapies, addressing a significant unmet medical need in this challenging patient population.

Addressing Critical Unmet Needs in Relapsed/Refractory Multiple Myeloma

Despite significant therapeutic advances, multiple myeloma remains incurable for the majority of patients, and several high-risk populations continue to face disproportionately poor outcomes. The past three years have seen intensified focus on identifying and addressing these gaps—spanning cytogenetic risk, treatment refractoriness, organ impairment, and resistance to emerging immunotherapies.

• High-risk cytogenetic subgroups, particularly del(17p): Patients harboring del(17p) represent a persistently difficult-to-treat population, with median PFS and OS of only 19.9 and 71.5 months, respectively, following upfront autologous SCT. Co-occurrence of del(17p) and t(4;14) confers especially poor prognosis, with median PFS and OS of just 11.5 and 22.4 months. While outcomes across high-risk cytogenetics broadly have improved over time—median PFS increasing from 13.7 to 36.8 months and median OS from 32.9 to 66.5 months between the 1988–2000 and 2016–2021 eras—novel targeted approaches remain an unmet need for these subgroups.

• Triple-class exposed and penta-refractory patients: Real-world data from triple-class exposed RRMM patients demonstrate uniformly poor outcomes, with ORR of only 23%, progressive disease in 61% at first subsequent therapy, and a median OS of just 5.4 months. In a real-world elranatamab cohort, 91% of patients were triple-class refractory and 49% were penta-refractory, underscoring the critical need for broader access to novel agents such as CAR-T cell therapies outside of clinical trial settings.

• Patients with severe renal impairment: This population is significantly underrepresented in pivotal trials—patients with creatinine clearance ≤30 mL/min were excluded from the MAIA trial—leaving an evidence gap in transplant-ineligible newly diagnosed MM with severe renal impairment. Retrospective data suggest frontline daratumumab-lenalidomide-dexamethasone (DRd) is active in this setting, with an overall hematologic response rate of 80%, VGPR or better in 50%, and complete renal response in 40%; deeper hematologic responses correlated with prolonged PFS and time to next treatment.

• Resistance to BCMA-directed and bispecific antibody therapies: Resistance to bispecific antibodies (BsAbs) represents a growing clinical challenge, arising through tumor-intrinsic mechanisms—including antigenic loss via target gene deletion or mutation, elevated soluble BCMA, high tumor burden, and extramedullary disease—as well as immune-mediated mechanisms related to T-cell exhaustion and an immunosuppressive tumor microenvironment. In real-world elranatamab data, prior BCMA-targeted therapy exposure (present in 49% of patients) was associated with reduced depth of response and inferior OS, particularly when the interval from prior BCMA therapy was less than one year.

• Optimal sequencing of T-cell redirecting therapies: As survival curves for T-cell redirecting (TCR) agents do not show a clear plateau, an increasing proportion of patients will require sequential TCR therapy. The field lacks robust guidance on optimal sequencing, necessitating individualized treatment decisions that account for tumor-specific features, prior therapy history, and patient fitness to preserve T-cell function and maximize outcomes across treatment lines.

KMCAR T-cell's Initial Safety Profile in the KOALA Phase I Trial

Three recent clinical studies highlight meaningful advances across the multiple myeloma treatment landscape. The OPTIMUM (MUKnine) trial evaluated daratumumab combined with low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) administered before and after autologous stem-cell transplant (ASCT) in newly diagnosed patients with molecularly defined ultra-high-risk multiple myeloma or plasma cell leukemia. At 30 months of follow-up, the regimen demonstrated compelling efficacy, with a progression-free survival (PFS) of 77% versus 39.8% in the comparator MyeXI trial, and overall survival (OS) of 83.5% versus 73.5%, respectively. Notably, a comparison of 18-month PFS yielded a 99.5% probability of OPTIMUM being superior to MyeXI. From a tolerability standpoint, extended post-ASCT Dara-VRd consolidation was highly deliverable with limited toxicity.

The MagnetisMM-1 trial investigated elranatamab monotherapy — a BCMA × CD3 bispecific antibody — in relapsed or refractory multiple myeloma. At a median follow-up of 12.0 months, the overall response rate (ORR) was 63.6%, with 38.2% of patients achieving a complete response or better and a median duration of response (DOR) of 17.1 months among responders. All 13 patients evaluable for minimal residual disease (MRD) achieved negativity, and even among patients with prior BCMA-directed therapy exposure, 53.8% responded. Median PFS and OS across all 55 patients were 11.8 months and 21.2 months, respectively. No dose-limiting toxicities were observed during dose escalation, though cytopenias and cytokine release syndrome (CRS) were noted as adverse events.

The AZD0120 (GC012F) Phase 1 study explored an autologous BCMA and CD19 dual-targeting CAR T-cell product as frontline therapy for newly diagnosed multiple myeloma patients aged ≥70, following two cycles of VRD induction. All patients achieved stringent complete response (sCR) and MRD negativity by Euroflow (10⁻⁶) at one month post-infusion, with MRD negativity rates sustained at 100% among evaluable patients at months 6 and 12. Notably, two frail patients with baseline ECOG status of 2 recovered to ECOG status of 1 following infusion. At a median follow-up of 9.8 months, hematologic toxicities were the most frequent grade ≥3 treatment-emergent adverse events, including neutropenia (75%), leukopenia (50%), and lymphopenia (25%). CRS occurred in 50% of patients, all grade 1, and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.